Description
Marc Ehrlich studied Biochemistry and Molecular Medicine at the Ruhr University Bochum, Germany. From 2012 to 2016, Marc did his PhD studies at the Max-Planck Insitute for Molecular Biomedicine in Münster, in the lab of Prof. Hans Schöler and at the Institute of Neuropathology of the University Hospital Münster, in the lab of Prof. Tanja Kuhlmann. Here, he focused on human induced pluripotent stem cells for disease modelling and pre-clinical drug discovery in the field of neurodegenerative diseases. Based on his findings during his PhD, Marc received a group leader grant from the state of North Rhine Westphalia to establish a university spin-off for pre-clinical drug discovery, which resulted in the foundation of the OliGo Technologies GmbH. Fascinated by the combination of (pre-)clinical research and strategic management, he joined in 2018 the Novartis Pharma GmbH in Nuremberg as Medical Advisor Neuroscience. In this position, he is responsible for clinical trials and medical projects in the indication of migraine.
